Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Recent Articles

Hengrui Launches Luzsana to Bring its Novel Medications to Global Markets
Laekna Raises $61 Million for its 14-Drug Cancer/Liver Disease Portfolio
Kelun Out-Licenses Global Rights for Candidate to Merck/MSD in $1.4 Billion Deal
Henlius Out-licenses Latin American Rights for Three Biosimilars in $55 Million Deal
Green Valley Stops Global Phase III Trial of its Novel China-Approved Alzheimer’s Drug
ChinaBio Event
Beijing and Digital
September 13-16, 2022
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
July 27-31, 2022